Cyrillic synonym: Интерлейкины.
Interleukins are cytokines that are thought to target leukocytes. As with other cytokines, interleukins are involved in the regulation of normal immune and inflammatory responses and have both proinflammatory and anti-inflammatory actions. Interleukins used clinically include interleukin-1, interleukin-2, and aldesleukin (recombinant interleukin-2). Interleukins under investigation include interleukin-3, ilodecakin (recombinant interleukin-10), and edodekin alfa (recombinant interleukin-12). Interleukins have also been implicated in the pathogenesis of some diseases, and inhibitors of interleukins or their receptors may therefore be of therapeutic value. Antagonists acting against interleukin receptors used clinically include anakinra (recombinant interleukin-1 receptor antagonist), basiliximab, and daclizumab, which are all interleukin-2 receptor antibodies, and tocilizumab (recombinant interleukin-6 receptor antibody) Inolimomab is an interleukin-2 receptor antibody under investigation. Antibodies targeting interleukins have been developed and those under investigation include mepolizumab (recombinant interleukin-5 antibody) and elsilimomab (recombinant interleukin-6 antibody). Interleukin fusion toxins are produced by combining interleukin protein sequences with a bacterial toxin (e.g. diphtheria or pseudomonas) with the aim of inhibiting specific interleukin activity. Those under investigation include interleukin-2 fusion toxins, interleukin-4 fusion toxins, and cintredekin besudotox, an interleukin-13 fusion toxin. Soluble interleukin receptors may have therapeutic value and are also being tried therapeutically: rilonacept is an interleukin-1 blocker used in the treatment of a group of rare inherited auto-inflammatory disorders; interleukin-4 receptor is also being investigated. Inhibitors of cysteine protease IL-1 β converting enzyme (ICE) have been investigated as a means of reducing secretion of interleukin-1β.
Published May 08, 2019.